Compare BridgeBio Pharma Inc (BBIO) vs Mercadolibre Inc (MELI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Mercadolibre Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Mercadolibre Inc trades at $1,932.27 (market cap $92.49B). The key difference: Mercadolibre Inc is far larger — about 5.6× BridgeBio Pharma Inc's market cap, and Mercadolibre Inc is trading nearer its 52-week high, BridgeBio Pharma Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | MELI | |
|---|---|---|
Market Cap | $16.61B | $92.49B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $2.51K |
52-Week Low | $47.29 | $1.55K |
Enterprise Value | $18.16B | $100.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
MercadoLibre (MELI) trades at $1,820.69, down 0.51% in the last 24 hours, with a bearish technical signal. The stock shows strong revenue growth, with Q2 2026 EPS beating estimates at $9.19 versus $8.65 expected, but recent quarters have missed expectations. Valuation ratios like P/E of 49.53 are elevated, while profitability metrics include a 42.68% gross margin and 27.5% ROE. Analyst consensus is strongly bullish with a $2,020 price target, but technical indicators suggest near-term weakness.
Outlook remains positive long-term due to robust e-commerce and fintech expansion in Latin America, with revenue projected to hit $35.2B in 2026. Risks include margin pressures from heavy investments and competitive threats. The stock offers growth potential if profit trends improve, but investors face volatility from strategic spending and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →
